KR970706842A - 아실화된 인슐린 동족체(Acylated Insulin Analogs) - Google Patents

아실화된 인슐린 동족체(Acylated Insulin Analogs)

Info

Publication number
KR970706842A
KR970706842A KR1019970703179A KR19970703179A KR970706842A KR 970706842 A KR970706842 A KR 970706842A KR 1019970703179 A KR1019970703179 A KR 1019970703179A KR 19970703179 A KR19970703179 A KR 19970703179A KR 970706842 A KR970706842 A KR 970706842A
Authority
KR
South Korea
Prior art keywords
insulin
acylated
homologue
lys
seq
Prior art date
Application number
KR1019970703179A
Other languages
English (en)
Inventor
제프리 클레이튼 베이커
죠제 미샤엘 앙뀌에
Original Assignee
피터 쥐. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 쥐. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 쥐. 스트링거
Publication of KR970706842A publication Critical patent/KR970706842A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 당뇨병 분야에 관한 것이다. 더 특히, 본 발명은 A 사슬은 천연의 사람 인슐린 A 서열이고, B 사슬은 B28 및 B29, 또는 모두에서 변경된, 단량체성 인슐린 동족체에 관한 것이다. 동족체는 A 사슬 또는 B 사슬의 N-말단 또는 라이신에서 일아실화된다. 아실화된 인슐린 동족체는 작용 지속시간이 연장된다.

Description

아실화된 인슐린 동족체(Acylated Insulin Analogs)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 서열 동정 번호 2에 적절하에 가교결합된 서열 동정 번호 1로 나타내어지는 일아실화된 인슐린 동족체, 또는 제약학적으로 허용가능한 그의 염.
  2. 제1항에 있어서, 서열 동정 번호 2의 28위치에서의 Xaa가 아실화된 라이신이고, 서열 동정 번호 2의 29위치에서의 Xaa가 프롤린인 아실화된 인슐린 동족체.
  3. 제2항에 있어서, 아실화기가 C6-C17지방산인 아실화된 인슐린 동족체.
  4. 제2항에 있어서, 아실화기가 C13-C17지방산인 아실화된 인슐린 동족체.
  5. B28-Nε-팔미토일-LysB28ProB29-사람 인슐린.
  6. B28-Nε-미리스토일-LysB28ProB29-사람 인슐린.
  7. 제1항 내지 6항 중 어느 한 항의 인슐린 동족체를 하나 이상의 제약학적으로 허용가능한 보존제, 등장화제 또는 완충제가 함께 포함하는 비경구 제약 제제.
  8. 인술린 또는 인슐린 동족체와 제1항 내지 7항 중 어느 한 항의 아실화된 인슐린 동족체와의 혼합물을 포함하고, 2가지 성분의 중량비가 약 1∼99 : 99∼1인 비경구 제약 제제.
  9. 제8항에 있어서, 혼합물이 LysB28ProB29-사람 인슐린과 B28-Nε-아실화된-LysB28ProB29-사람 인슐린의 혼합물인 비경구 제약 제제.
  10. 제1항 내지 7항 중 어느 한 항의 아실화된 인슐린 동족체의 유효량을 포함하는 제약 조성물을 환자에게 투여하는 것을 포함하는, 고혈당증 환자의 치료 방법.
  11. 제1항 내지 7항 중 어느 한 항의 화합물, 등장화제 및 생리적으로 허용되는 완충제를 혼합하는 것을 포함하는 비경구 제약 제제의 제조 방법.
  12. 당뇨병 치료에서 유용한 제1항 내지 7항 중 어느 한 항에 따른 아실화된 인슐린 동족체.
  13. 실질적으로 모든 실시예에 기재된 아실화된 인슐린 동족체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970703179A 1994-11-17 1995-11-14 아실화된 인슐린 동족체(Acylated Insulin Analogs) KR970706842A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/342,931 US5693609A (en) 1994-11-17 1994-11-17 Acylated insulin analogs
US08/342,931 1994-11-17

Publications (1)

Publication Number Publication Date
KR970706842A true KR970706842A (ko) 1997-12-01

Family

ID=23343907

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703179A KR970706842A (ko) 1994-11-17 1995-11-14 아실화된 인슐린 동족체(Acylated Insulin Analogs)

Country Status (25)

Country Link
US (2) US5693609A (ko)
EP (1) EP0712861B1 (ko)
JP (1) JPH10511644A (ko)
KR (1) KR970706842A (ko)
AR (1) AR002700A1 (ko)
AT (1) ATE237635T1 (ko)
AU (1) AU711282B2 (ko)
BR (1) BR9509653A (ko)
CA (1) CA2205060A1 (ko)
CO (1) CO4520284A1 (ko)
CZ (1) CZ145797A3 (ko)
DE (1) DE69530353T2 (ko)
ES (1) ES2194890T3 (ko)
FI (1) FI972031A (ko)
HU (1) HUT77030A (ko)
IL (1) IL115973A (ko)
NO (1) NO972169L (ko)
NZ (1) NZ297257A (ko)
PL (1) PL320644A1 (ko)
RU (1) RU2160118C2 (ko)
TR (1) TR199501420A2 (ko)
TW (1) TW434259B (ko)
WO (1) WO1996015804A1 (ko)
YU (1) YU71395A (ko)
ZA (1) ZA959679B (ko)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537524A1 (en) * 1991-10-17 1993-04-21 Shipley Company Inc. Radiation sensitive compositions and methods
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
ATE273320T1 (de) * 1996-04-11 2004-08-15 Univ British Columbia Fusogene liposomen
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
AU3255297A (en) * 1996-07-11 1998-02-09 Novo Nordisk A/S Selective acylation method
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
CN1276731A (zh) * 1997-10-24 2000-12-13 伊莱利利公司 不溶性胰岛素组合物
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US6159931A (en) * 1998-09-29 2000-12-12 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
WO2000073793A2 (en) * 1999-05-27 2000-12-07 Cecil Yip Identification of compounds modulating insulin receptor activity
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
HU229310B1 (en) * 1999-10-29 2013-10-28 Nektar Therapeutics Dry powder compositions having improved dispersivity
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7905230B2 (en) * 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003000326A1 (en) * 2001-06-20 2003-01-03 Nektar Therapeutics Powder aerosolization apparatus and method
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
DK1436012T3 (en) * 2001-10-18 2018-01-22 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
AU2002351271A1 (en) * 2001-12-21 2003-07-24 Nektar Therapeutics Capsule package with moisture barrier
EP1472140A1 (en) * 2001-12-21 2004-11-03 Nektar Therapeutics Apparatus and method for sealing cavities
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US6941980B2 (en) * 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
JP4654033B2 (ja) * 2002-10-23 2011-03-16 バークシス コーポレーション 効率的なプレ−トランス−スプライシング分子の同定のためのスクリーニング方法
US7516741B2 (en) * 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
US20040206350A1 (en) * 2002-12-19 2004-10-21 Nektar Therapeutics Aerosolization apparatus with non-circular aerosolization chamber
US20050236296A1 (en) * 2002-12-30 2005-10-27 Nektar Therapeutics (Formerly Inhale Therapeutic Systems, Inc.) Carry case for aerosolization apparatus
MXPA05007154A (es) 2002-12-30 2005-09-21 Nektar Therapeutics Atomizador prepeliculizacion.
US7669596B2 (en) * 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
US7208145B2 (en) 2002-12-31 2007-04-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
DK1615689T3 (da) 2003-04-09 2016-03-14 Novartis Ag Apparatur til dannelse af en aerosol og omfattende en opretningsføring til punktering af en kapsel
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
MXPA05010842A (es) 2003-04-09 2006-03-30 Nektar Therapeutics Aparato de nebulizacion con protector de entrada de aire.
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
EP2085406A1 (en) * 2003-07-25 2009-08-05 ConjuChem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
SI1675622T1 (sl) 2003-09-17 2017-09-29 Nektar Therapeutics Večkraka polimerna predzdravila
WO2005044226A2 (en) * 2003-11-04 2005-05-19 Nectar Therapeutics Lipid formulations for spontaneous drug encapsulation
US20050214250A1 (en) 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
US7790835B2 (en) * 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
ES2733764T3 (es) 2003-12-16 2019-12-02 Nektar Therapeutics Método para la preparación de oligo etilenglicol monodisperso
EP1701714A2 (en) * 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
WO2005107815A2 (en) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Polymer derivatives comprising an imide branching point
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
EP2626368B1 (en) 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006082205A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
JP5087539B2 (ja) * 2005-05-18 2012-12-05 ネクター セラピューティックス 気管支内治療のためのバルブ、デバイス、および方法
JP5600240B2 (ja) * 2005-07-19 2014-10-01 ウェルズ ファーゴ バンク ナショナル アソシエイション 重合体マレイミド類を調製する方法
AU2006275473B2 (en) 2005-07-29 2012-07-05 Nektar Therapeutics Methods for preparing carbonate esters of poly(ethylene glycol)
ES2368500T3 (es) 2005-08-16 2011-11-17 Novo Nordisk A/S Método para producir polipéptidos de insulina maduros.
KR101424518B1 (ko) 2005-09-29 2014-08-06 노바르티스 아게 항생제 제형, 단위 투여체, 키트 및 방법
US20090032427A1 (en) * 2005-09-29 2009-02-05 Nektar Therapeutics Receptacles and Kits, Such as for Dry Powder Packaging
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
EP1984009B1 (en) * 2006-01-18 2012-10-24 Qps, Llc Pharmaceutical compositions with enhanced stability
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
KR101441444B1 (ko) * 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
JP5231412B2 (ja) 2006-07-11 2013-07-10 キューピーエス リミテッド ライアビリティ カンパニー ペプチドを持続的放出により送達するための薬理組成物
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
EP2668970B1 (en) * 2006-10-25 2016-07-06 Novartis AG Powder dispersion apparatus
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
CN101677944A (zh) * 2007-06-01 2010-03-24 诺沃-诺迪斯克有限公司 稳定的非含水药物组合物
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009022013A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
AU2008313248B2 (en) 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
JP5350388B2 (ja) * 2007-10-25 2013-11-27 ノバルティス アーゲー 単位用量薬物パッケージの粉体調整
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
PT2285439E (pt) 2008-04-04 2014-03-25 Nektar Therapeutics Dispositivo de aerossolização
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US8492503B2 (en) 2008-09-11 2013-07-23 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
BRPI0919946A2 (pt) * 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND USES THEREOF
US8906850B2 (en) 2009-01-28 2014-12-09 Smartcells, Inc. Crystalline insulin-conjugates
US8846103B2 (en) 2009-01-28 2014-09-30 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
ES2791683T3 (es) 2009-01-28 2020-11-05 Smartcells Inc Sistemas a base de conjugados para la administración controlada de fármacos
JP2012517459A (ja) 2009-02-12 2012-08-02 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 代謝障害治療のためのカルジオトロフィン１の使用
EP3552603A1 (en) 2009-03-18 2019-10-16 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2768379C (en) 2009-07-17 2017-10-10 David Mark Blakey Negatively biased sealed nebulizers systems and methods
CA2782056C (en) 2009-11-25 2021-03-09 Arisgen Sa Mucosal delivery of peptides
JP2013517099A (ja) 2010-01-19 2013-05-16 ネクター セラピューティクス ドライのネブライザ要素の識別
CA2805902A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
EP2598527A4 (en) 2010-07-28 2014-01-08 Smartcells Inc RECOMBINANT EXPRESSED INSULIN POLYPEPTIDES AND APPLICATIONS THEREOF
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
AU2012351947B2 (en) 2011-12-16 2017-08-17 Novartis Ag Aerosolization apparatus for inhalation profile-independent drug delivery
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
GB2516388A (en) 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
ES2676065T3 (es) 2013-10-07 2018-07-16 Novo Nordisk A/S Nuevo derivado de un análogo de la insulina
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
WO2017127420A1 (en) 2016-01-19 2017-07-27 Nektar Therapeutics Sealed liquid reservoir for a nebulizer
EP3411030A4 (en) 2016-02-01 2019-09-04 InCarda Therapeutics, Inc. COMBINING ELECTRONIC SURVEILLANCE WITH INHALATION PHARMACOLOGICAL THERAPY FOR MANAGING CARDIAC ARRHYTHMIAS WITH ATRIAL FIBRILLATION
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
EP3621616A4 (en) 2017-05-10 2021-01-13 InCarda Therapeutics, Inc. UNIT DOSE, AEROSOLS, KITS AND METHODS FOR TREATMENT OF HEART DISEASE BY PULMONAL ADMINISTRATION
MX2020001434A (es) 2017-08-17 2020-03-20 Novo Nordisk As Analogos de insulina acilados novedosos y usos de estos.
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20220019027A (ko) 2019-06-10 2022-02-15 레스피라 테라퓨틱스 인크. 담체-기반 제제 및 관련 방법
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
MX2022012208A (es) 2020-03-31 2022-12-15 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales.
JP7456007B2 (ja) * 2020-05-15 2024-03-26 イーライ リリー アンド カンパニー 長時間作用アシル化インスリン化合物
AU2021382599A1 (en) 2020-11-19 2023-06-22 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1902865A1 (de) * 1968-02-01 1969-09-11 American Home Prod Substituierte Insulin-Derivate,Verfahren zu ihrer Herstellung und ihre Verwendung in pharmazeutischen Zubereitungen
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) * 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
BE791949A (fr) * 1971-11-27 1973-05-28 Schering Ag Derives d'insuline, leur preparation et leur utilisation
US3896437A (en) * 1973-10-11 1975-07-22 Sperry Rand Corp Apparatus for generating precise crossover frequency of two independent equal bandwidth spectra
GB1492997A (en) * 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
AU8091091A (en) * 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
BR9407508A (pt) * 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AU720966B2 (en) * 1995-03-17 2000-06-22 Novo Nordisk A/S Insulin derivatives

Also Published As

Publication number Publication date
RU2160118C2 (ru) 2000-12-10
FI972031A0 (fi) 1997-05-13
IL115973A (en) 2001-08-26
BR9509653A (pt) 1997-09-16
AU4237396A (en) 1996-06-17
CZ145797A3 (en) 1997-12-17
JPH10511644A (ja) 1998-11-10
FI972031A (fi) 1997-05-14
EP0712861A3 (en) 1998-03-11
US5922675A (en) 1999-07-13
TR199501420A2 (tr) 1996-06-21
US5693609A (en) 1997-12-02
CA2205060A1 (en) 1996-05-30
NO972169D0 (no) 1997-05-12
PL320644A1 (en) 1997-10-13
DE69530353D1 (de) 2003-05-22
IL115973A0 (en) 1996-01-31
EP0712861A2 (en) 1996-05-22
ATE237635T1 (de) 2003-05-15
ZA959679B (en) 1997-05-14
DE69530353T2 (de) 2004-02-19
MX9703508A (es) 1997-07-31
EP0712861B1 (en) 2003-04-16
WO1996015804A1 (en) 1996-05-30
TW434259B (en) 2001-05-16
AR002700A1 (es) 1998-04-29
NZ297257A (en) 1999-05-28
HUT77030A (hu) 1998-03-02
ES2194890T3 (es) 2003-12-01
AU711282B2 (en) 1999-10-07
CO4520284A1 (es) 1997-10-15
NO972169L (no) 1997-05-12
YU71395A (sh) 1998-07-10

Similar Documents

Publication Publication Date Title
KR970706842A (ko) 아실화된 인슐린 동족체(Acylated Insulin Analogs)
RU97110125A (ru) Ацилированные аналоги инсулина
ES2291017T3 (es) Efectos inotropicos y diureticos de la exendina y glp-1.
EP1629849B1 (en) Pharmaceutical compositions comprising exendins and agonists thereof
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
KR960000923A (ko) 단량체성 인슐린 유사체의 제제
RU2010151656A (ru) Аналоги глюкагона, обладающие повышенной растворимостью и стабильностью в буферах с физиологическими значениями ph
JP2003519667A (ja) トリグリセリドレベルの調節および脂質異常血症の治療のためのエキセンジンおよびそのアゴニストの使用
UA26874C2 (uk) Пареhтеральhа фармацевтичhа композиція
BR9813111A (pt) Composições de insulina insolúveis
KR880001701A (ko) 신규한 펩티드
AU2010200224A1 (en) GRF Analog Compositions and Their Use
KR880000463A (ko) 사슬 결합법
FI93308B (fi) Menetelmä somatostatiinia sisältävän farmaseuttisen ainekoostumuksen valmistamiseksi
KR950701818A (ko) 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
KR900003205A (ko) 제약 화합물
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
KR910000794A (ko) Vip-유사체 ⅱ
DE60028559T2 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
AR032461A1 (es) Componente farmaceutico que comprende un peptido de la hormona paratiroidea humana o su derivado y acido acetico, composicion farmaceutica para la administracion intranasal que comprende dicho componente, y producto farmaceutico que comprende dicho componente
SE9201584D0 (sv) Use of alpha-ketoglutarate
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
RU2119800C1 (ru) Аналог пептида фактора гормона роста (фгр), способ стимулирования секреции гормона роста и композиция для стимулирования секреции
KR920700675A (ko) 발기 기능장해 치료용 약물(칼시토닌 유전자 관련 펩티드)
AU734304B2 (en) Acylated insulin analogs

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application